Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
Descripción del Articulo
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma in adults, with a high mortality rate. Low serum albumin can be a biological indicator of the disease reflected as increased inflammation or increased toxicities. Currently, the International Progn...
Autores: | , , , , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2024 |
Institución: | Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
Repositorio: | Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
Lenguaje: | español |
OAI Identifier: | oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/2225 |
Enlace del recurso: | https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225 |
Nivel de acceso: | acceso abierto |
Materia: | Linfoma de Células B Grandes Difuso Pronóstico Albúmina Supervivencia Biomarcadores Diffuse Large B-Cell Lymphoma Prognosis Albumin Survival Biomarkers |
id |
REVCMH_5dc75a6aefa1d1d33a405450ab1c7430 |
---|---|
oai_identifier_str |
oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/2225 |
network_acronym_str |
REVCMH |
network_name_str |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
repository_id_str |
|
dc.title.none.fl_str_mv |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru Albúmina como factor pronóstico en sobrevida de pacientes con linfoma difuso de células B grande atendidos en un hospital de Lima, Perú |
title |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru |
spellingShingle |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru Morales-Cuzquén , Luis Gustavo Linfoma de Células B Grandes Difuso Pronóstico Albúmina Supervivencia Biomarcadores Diffuse Large B-Cell Lymphoma Prognosis Albumin Survival Biomarkers |
title_short |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru |
title_full |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru |
title_fullStr |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru |
title_full_unstemmed |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru |
title_sort |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru |
dc.creator.none.fl_str_mv |
Morales-Cuzquén , Luis Gustavo Vela-Ruiz, José Manuel Ferrer-Ponce, Diana I. Fernandez-Anccas , Cesar Roldán-Arbieto, Luis Beltrán-Garate , Brady Ernesto Villela, Luis De La Cruz-Vargas, Jhony A. |
author |
Morales-Cuzquén , Luis Gustavo |
author_facet |
Morales-Cuzquén , Luis Gustavo Vela-Ruiz, José Manuel Ferrer-Ponce, Diana I. Fernandez-Anccas , Cesar Roldán-Arbieto, Luis Beltrán-Garate , Brady Ernesto Villela, Luis De La Cruz-Vargas, Jhony A. |
author_role |
author |
author2 |
Vela-Ruiz, José Manuel Ferrer-Ponce, Diana I. Fernandez-Anccas , Cesar Roldán-Arbieto, Luis Beltrán-Garate , Brady Ernesto Villela, Luis De La Cruz-Vargas, Jhony A. |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
Linfoma de Células B Grandes Difuso Pronóstico Albúmina Supervivencia Biomarcadores Diffuse Large B-Cell Lymphoma Prognosis Albumin Survival Biomarkers |
topic |
Linfoma de Células B Grandes Difuso Pronóstico Albúmina Supervivencia Biomarcadores Diffuse Large B-Cell Lymphoma Prognosis Albumin Survival Biomarkers |
description |
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma in adults, with a high mortality rate. Low serum albumin can be a biological indicator of the disease reflected as increased inflammation or increased toxicities. Currently, the International Prognostic Index (IPI) is the accepted model for prognosis in patients with DLBCL. Objective: To determine the prognostic value of albumin in overall survival (OS) of patients with DLBCL treated with immunochemotherapy in a hospital in Peru during the period 2017-2019. Materials and methods: Analytical, cross-sectional, retrospective and observational study. It consisted of 161 patients with DLBCL diagnosed and treated during the mentioned period. The SPSS v27 program was used for statistical analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the prognostic impact of albumin on overall survival (OS). Results: The OS of patients up to 12 months was 94%, 3 years was 87%, and 5 years was 87%. In multivariate Cox proportional hazards regression analysis, albumin (p=0.037; HR=3.614 95% CI [1.079 – 12.105]) and IPI (p=0.017; HR 1.891 95% CI [1.121 – 3.19]) were found to be the independent variables influencing OS in patients with DLBCL. Conclusions: Hypoalbuminemia might be a risk factor for shorter OS. In association with the IPI, a cumulative prognostic scoring system could be developed in patients with DLBCL. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-11-07 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225 10.35434/rcmhnaaa.2024.174.2225 |
url |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225 |
identifier_str_mv |
10.35434/rcmhnaaa.2024.174.2225 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225/964 |
dc.rights.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo |
publisher.none.fl_str_mv |
Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo |
dc.source.none.fl_str_mv |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 No. 4 (2024): Rev. Cuerpo Med. HNAAA, October - December; e2225 Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 Núm. 4 (2024): Rev. Cuerpo Med. HNAAA, Octubre - Diciembre; e2225 2227-4731 2225-5109 10.35434/rcmhnaaa.2024.174 reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo instname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo instacron:HNAAA |
instname_str |
Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
instacron_str |
HNAAA |
institution |
HNAAA |
reponame_str |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
collection |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1842629794589573120 |
spelling |
Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, PeruAlbúmina como factor pronóstico en sobrevida de pacientes con linfoma difuso de células B grande atendidos en un hospital de Lima, PerúMorales-Cuzquén , Luis GustavoVela-Ruiz, José ManuelFerrer-Ponce, Diana I.Fernandez-Anccas , CesarRoldán-Arbieto, LuisBeltrán-Garate , Brady Ernesto Villela, LuisDe La Cruz-Vargas, Jhony A.Linfoma de Células B Grandes DifusoPronósticoAlbúminaSupervivenciaBiomarcadoresDiffuse Large B-Cell LymphomaPrognosisAlbuminSurvivalBiomarkersIntroduction: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma in adults, with a high mortality rate. Low serum albumin can be a biological indicator of the disease reflected as increased inflammation or increased toxicities. Currently, the International Prognostic Index (IPI) is the accepted model for prognosis in patients with DLBCL. Objective: To determine the prognostic value of albumin in overall survival (OS) of patients with DLBCL treated with immunochemotherapy in a hospital in Peru during the period 2017-2019. Materials and methods: Analytical, cross-sectional, retrospective and observational study. It consisted of 161 patients with DLBCL diagnosed and treated during the mentioned period. The SPSS v27 program was used for statistical analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the prognostic impact of albumin on overall survival (OS). Results: The OS of patients up to 12 months was 94%, 3 years was 87%, and 5 years was 87%. In multivariate Cox proportional hazards regression analysis, albumin (p=0.037; HR=3.614 95% CI [1.079 – 12.105]) and IPI (p=0.017; HR 1.891 95% CI [1.121 – 3.19]) were found to be the independent variables influencing OS in patients with DLBCL. Conclusions: Hypoalbuminemia might be a risk factor for shorter OS. In association with the IPI, a cumulative prognostic scoring system could be developed in patients with DLBCL.Introducción: El linfoma difuso de células B grandes (LDCGB) es la forma más prevalente del linfoma no Hodgkin en adultos, tiene una alta tasa de mortalidad. La albumina sérica baja puede ser un indicador biológico de la enfermedad reflejado como un aumento de la inflamación o aumento en toxicidades. Actualmente el Índice Pronóstico Internacional (IPI) es el modelo aceptado para pronóstico en pacientes con LDCGB. Objetivo: Determinar el valor pronóstico de la albumina en la supervivencia global (SG) de pacientes con LDCGB tratados con inmunoquimioterapia en un hospital de Perú durante el período 2017–2019. Material y método: Estudio analítico, transversal, retrospectivo y observacional. Constó con 161 pacientes con LDCGB diagnosticados y tratados durante el periodo mencionado. Se utilizó el programa SPSS v27 para el análisis estadístico. Se utilizaron cocientes de riesgos (HR) e intervalos de confianza (IC) del 95 %, para evaluar el impacto pronóstico de la albúmina en la supervivencia global (SG). Resultados: La SG de pacientes fue de hasta 12 meses del 94%, de 3 años fue 87% y de 5 años fue del 87%. En el análisis multivariado de regresión de riesgos proporcionales Cox, se observó que la albúmina (p=0,037; HR=3.614 IC 95% [ 1.079 – 12.105]) y el IPI (p=0,017; HR 1.891 IC 95% [1.121 – 3.19]) fueron las variables independientes con influjo en la SG de los pacientes con LDCGB. Conclusiones: La hipoalbuminemia podría ser un factor de riesgo para una SG más corta. Asociado con el IPI, se podría desarrollar un sistema de puntuación pronóstico acumulativo en pacientes con LDCGB.Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo2024-11-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/222510.35434/rcmhnaaa.2024.174.2225Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 No. 4 (2024): Rev. Cuerpo Med. HNAAA, October - December; e2225Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 Núm. 4 (2024): Rev. Cuerpo Med. HNAAA, Octubre - Diciembre; e22252227-47312225-510910.35434/rcmhnaaa.2024.174reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstacron:HNAAAspahttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225/964Derechos de autor 2024 Luis Gustavo Morales-Cuzquén , José Manuel Vela-Ruiz, Diana I. Ferrer-Ponce, Cesar Fernandez-Anccas , Luis Roldán-Arbieto, Brady Ernesto Beltrán-Garate , Luis Villela, Jhony A. De La Cruz-Vargashttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/22252025-05-19T04:52:26Z |
score |
12.641649 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).